Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Changhai Hospital
National Cancer Institute (NCI)
Region Skane
Hôpital Edouard Herriot
Emory University
Mayo Clinic
Nantes University Hospital
Odense University Hospital
Odense University Hospital
Fudan University
City of Hope Medical Center
Case Western Reserve University
Servicio de Salud Metropolitano Sur Oriente
Sun Yat-sen University
City of Hope Medical Center
Oslo University Hospital
Vanderbilt-Ingram Cancer Center
Saint Vincent's Hospital, Korea
University of Exeter
Sahlgrenska University Hospital
National Health Service, United Kingdom
Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University
E-DA Hospital
E-DA Hospital
Mayo Clinic
Memorial University of Newfoundland
University of Nottingham
University of Cambridge
UMC Utrecht
Region Örebro County
Odense University Hospital
Radboud University Medical Center
M.D. Anderson Cancer Center
Johann Wolfgang Goethe University Hospital
Gloucestershire Hospitals NHS Foundation Trust
Washington University School of Medicine
Washington University School of Medicine
Royal Marsden NHS Foundation Trust
Catholic University of the Sacred Heart
University of Florida
Changhai Hospital
University Medical Center Groningen
Clinical Research Support Center Kyush
S.L.A. Pharma AG
King Chulalongkorn Memorial Hospital
National Cancer Institute (NCI)
Valley Health System